Continuous glucose monitoring use was similar (50.3% vs 47.9%), insulin pump use was >2 × higher (40.7% vs 17%), and automated insulin delivery use was >3 × higher (20.4% vs 6.4%) in the T1DX-QI as compared to the DPV.<h4>Conclusion</h4>Despite a high prevalence of ASCVD and risks of hypoglycemia, guideline-recommended treatments including lipid-lowering therapy for secondary prevention and diabetes technologies were used in approximately half or fewer of older adults with T1D. Here, INS is linked to type 1 diabetes mellitus.